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Abstract: Over the past century, advances in biomedical
technologies have resulted in a need for government
regulation of the distribution of genetic modification and
medical enhancements. Without these regulations, the poor
of Appalachia will suffer immensely from the lack of
protection against genetic diseases, and disorders, and
lack of opportunity for genetic enhancements, and will
eventually fall further behind more developed and wealthy
areas regarding their health and quality of life. She
suggests that government regulations such as implementing
systems focused around utilitarianism, prioritarianism, and
equality could help to reverse this effect of poverty and
unequal distribution of health.
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The Appalachian Dilemma: An Ethical Debate on Genetic
Therapy and Genetic Enhancement
In the past century, advances in biomedical
technologies have increased exponentially and are projected
to maintain that trend in the future. With any new
technology comes new issues that have to be resolved. For
example, genetic engineering of crops has the potential to
increase agricultural productivity, however, it poses very
serious environmental risks that must be considered
(Altieri, 2000). In the same way, biomedical technology
brings with it new medical procedures, and with new medical
procedures comes a great deal of biomedical ethical
disputes that then spread throughout the biotechnical and
biomedical communities. One highly debated matter within
the biomedical community surrounds the just distribution of
healthcare.

In America, this matter centers itself around the
impoverished of the country—or those who cannot pay for
medical services as readily as the wealthier classes.
Appalachia is known for many things, a few being the lack
of education and the abundance of poverty within the region
over a very long span of time. Therefore, this lack of
wealth results in an absence of proper health care.
Appalachia falls behind in many rankings. “In [Appalachian
settlements], in which virtually everyone [is] at risk of
poor health outcomes…” individuals wonder why some families
have incredibly sick children and other do not. It boils
down to the wealth and education of the parents of those
children (Erwin, 2008).
With new biomedical technologies and procedures, the
ability to prevent genetic diseases and disorders and
genetically enhance offspring has become possible (Sankar,
2015). With the effects of poverty in Appalachia, the
ability for individuals to receive this treatment would be
minimal if treatment is given only to those who have the
means to pay for it on their own without the help of health
insurance coverage. Government regulations such as
implementing systems focused around utilitarianism,
prioritarianism, and equality could help to reverse this
effect of poverty with the just distribution of health
2

care, but the principles of biomedical ethics must
contribute to the making of any policies or allocation
system. Otherwise, the three ethical topics must all
promote each other equally which can only happen in certain
situations. Without proper ethical policy to regulate the
usage and distribution of new genetic biomedical
technologies, the poor of Appalachia will suffer immensely
from the lack of protection against genetic diseases and
the lack of opportunity for enhancements past a basic
healthcare need.

The CRISPR-Cas9 System: A Solution
Thanks to biomedical technology and advances in
biomedical sciences, it is commonly known that every cell
in the human body has a copy of that individual’s genome.
Advances in genetic sequencing have allowed researchers to
make connections between the genome and a variety of
diseases. After learning the major effect of the genome on
a person’s health, scientists began looking for ways to
safely alter the genome as a solution to these diseases.
Although other solutions have been discovered, the CRISPRCas9 system is the most inexpensive, effective, and
therefore the most efficient method of altering the genome.
Jeffry D. Sander and J. Keith Joung claim that even though
3

“the genome-wide specificities of CRISPR-Cas9 systems
remain to be fully defined, the capabilities of these
systems to perform targeted, highly efficient alterations
of genome sequence and gene expression will undoubtedly
transform biological research and spur the development of
novel molecular therapeutics for human disease” (Sander,
2014). The biomedical technology presents the ability to
engineer biological systems and organisms and this has
enormous potential for applications across science,
medicine, and biotechnology (Ran, 2013). CRISPR technology,
or clustered regularly interspaced short palindromic
repeat, is an adaptable immune mechanism that is used in
nature by bacteria to protect itself from viral infections
and from plasmids, meaning it is not “new” technology in
the sense, but is being applied in a new way. The
development of this recombinant DNA technology began in the
1970’s, but recent advances in the technologies have begun
a sort of biotechnological revolution (Hsu, 2014).

How Does It Work?
What is the CRISPR-Cas9 system and what does it
actually do? Simply, it can remove one piece of DNA and
replace it with another piece. For example, if someone has
a gene that makes them more susceptible to a certain
4

disease, the CRISPR-Cas9 system could cut that piece of DNA
out of the genome, and insert a new and healthy gene in its
place. Within the cell, the system is not much more
complex. Clustered regularly interspaced short palindromic
repeats or CRISPR, CRISPR Associated genes (Cas) and the
Cas protein (Cas9) are the main factors in this technology
(Scherz, 2017).
To begin, the use of CRIPSR-Cas9 in nature must be
discussed, and that involves the defense mechanism used by
bacteria to protect itself against viral infection. To
infect bacteria, viruses inject their DNA into the
bacteria. To defend themselves from viral infection,
bacteria use the CRISPR-Cas9 system to cut the viral
deoxyribonucleic acid or DNA and hinder it mutated or
nonfunctioning. The bacteria capture segments of DNA from
invading viruses and use the sequences to create the DNA
segments that are between the regularly-interspaced short
palindromic repeats in CRISPR. The sequences used to
identify viruses is a sort of archive of past attacks and
is used to protect against attacks by those viruses again.
Cas9, a CRISPR associated gene protein, is transcribed when
virus DNA is detected, and it is an enzyme that acts as a
pair of molecular scissors. This protein is targeted by
guide ribonucleic acid or gRNA, also known as crRNA or
5

CRISPR RNA, and it then binds to the gRNA or crRNA that is
produced from the CRISPR segments making the CRISPR-Cas9
complex. The gRNA or crRNA binds to Cas9 and to the
specific sequence in the DNA that has been selected for
editing. The gRNA or crRNA has RNA bases that are
complementary, by Wilson and Crick standards, to the bases
of the target DNA sequence. The Virus DNA binds to the
target sequence within the complex, and the DNA is pulled
apart. Although the specific sequence within these crRNAs
that targets DNA normally pairs to viral DNA, which is the
natural mechanism for CRISPR-Cas9 antiviral defense in
bacteria, the sequence can very easily be replaced by a
sequence of interest to alter a specific piece of the
genome. Then, Cas9 cuts the gene so that it is free from
the rest of the sequence of DNA. When the two pieces of DNA
are released, they try to come back together and mutations
occur, disabling the gene altogether. Once the DNA is cut,
researchers can use the cell’s own DNA repair machinery to
add or delete pieces of genetic material, or replace the
gene with a customized piece of DNA. (Reis, et. al, 2014).

How will this be applied in healthcare treatments?
The clinical application of this technology has a few
specificities. Treatment with the CRISPR-Cas9 therapy comes
6

in different forms. In most applications, the genetically
modified cells are injected into the patient. The patient
could either be an embryo still in development or could be
a living individual. The injection could either effect the
somatic cells of the patient, which would alter their
genome in a way that was not then passed down to the
patient’s offspring. On the other hand, the patient could
be treated as an embryo or treated for cells that affect
the reproductive organs of that individual, referred to as
germline genome editing (Nicol, 2017). These new genetic
modifications would be passed on to that individual’s
offspring.

Main Biomedical Ethical Issues
Although there are numerous biomedical ethical issues
that need to be confronted, one of the most significant as
of recent surrounds genetic modification technology. Eric
Juengst’s

“Crowdsourcing the Moral Limits of Human Gene

Editing?” confronts one of the most well-known and hotbutton ethical dilemmas of genetic modification. The
dilemma is the ethical implications of “two kinds of
potential gene-editing experiments in humans: those making
inheritable germ-line modifications and those designed to
enhance human traits beyond what is necessary for health
7

and healing” (Juengst, 2017). These two genetic
modifications must be defined.

Somatic vs. Germline
The genetic modifications that are “making inheritable
germ-line modifications” must be compared to the genetic
modifications that do not (Jeungst). In the same way,
genetic modification that is “designed to enhance human
traits beyond what is necessary for health and healing”
must be compared to genetic modification that is designed
to treat for the patient’s health and healing.
Somatic-cell genetic enhancement includes genetic
modification that introduces new, modified cells to
nonreproductive cells. This would prevent them from being
passed down to future generations. Germ-line genetic
enhancement includes the introduction of genetically
modified cells into reproductive cells, including the
sperm, ova, or preimplantation embryos. The changes would
then result in an alteration that is then passed down in
the genome. (Degrazia, et.al, 2011)

Therapy vs. Enhancement
Therapeutic genetic engineering, commonly called
“genetic therapy,” includes interventions that are directed
8

at the cure of genetic disease. Nontherapeutic genetic
engineering, or “genetic enhancement,” includes
interventions directed towards the alteration and
enhancement of human traits and capabilities such as
height, strength, or intelligence. (Degrazia)

Current Ethical Policy
United States
Erwin dissects a consensus made by the United States’
National Academies of Science, Engineering, and Medicine
(NASEM) in 2017 that can be described as ‘opening the door’
to the ethical conversation regarding genetic modification.
In the end, they decided it was critical to allow diverse
public input and voice in the policy-making process
regarding the framework for ethical decision making in
genetic enhancements and modification. Although this is a
start to the discussion of biomedical ethical policy, still
no actual action was taken to create a policy surrounding
this major dilemma. It is imperative that this is one of
the first ethical issues that has policy to regulate it.

United Kingdom
In the United Kingdom, the Nuffield Council on
Bioethics published a report of the ethical and social
9

implications raised by heritable genetic and genome editing
treatments. They came to the conclusion in July of 2018
that the use of genetic modification could be morally
permissible in some circumstances. The recommendation given
by the counsel was as follows:
“Any use of genome editing interventions should be
guided by two overarching principles: they must be
intended to secure, and be consistent with, the
welfare of the future person; and they should not
increase disadvantage, discrimination, or division in
society. More work needs to be done to establish
whether these principles can be met. (Nuffield Council
on Bioethics, 2018).”
The council began to work on their report in September of
2016.

China
On the other hand, Chinese geneticists’ views of
ethical issues are much different than that of geneticist
in both America and the United Kingdom. China has made
genetics a priority for decades. In the 1960’s,
cytogenetics technology was introduced, and then in the
1970’s, chronic villi sampling was performed (Mao). Now,
reports have been made that a successful genetic
10

modification on an embryo has been performed in China.
Because of the cultural difference between the UK and
America, and China, China has already begun very serious
human trial research.

What will the insurance pay for?
According to the U.S. National Library of Medicine,
health insurance plans in many cases will cover the costs
of genetic testing when recommended or suggested by the
person’s physician. Most insurance companies today will pay
for at least some genetic counseling and genetic testing.
An example of this is that under the Affordable Care Act,
both genetic counseling and BRCA gene testing in females (a
gene associated with breast cancer) is covered. There are
differences in policies per provider when it comes down to
which tests are covered, and many individuals opt out of
having their insurance company paying for genetic testing.
This is due to the fact that genetic tests can result in a
person’s insurance coverage being effected.
However, the issue of insurance companies covering the
costs of genetic modification is a different story. In the
United States, there has been little-to-no discussion on
the topic of coverage regarding genetic modification. In
other countries, like the United Kingdom, there is at least
11

some discussion happening. However, in the United Kingdom,
the discussion on insurance policy regarding genetic
modification is focused mainly on the coverage issues
regarding genetically modified products instead of the
issues regarding the genetic modification of humans
(James). Most likely, insurance companies will cover the
cost of genetic modification for therapy and not
enhancement. This aligns well with previous ethical and
insurance policy decisions of the United States regarding
the personal payment for cosmetic treatment that does not
directly affect the person’s health, and the coverage of
procedures directly related to health benefits. If someone
decided to get facial reconstruction surgery because their
cheekbones were too low for their liking, insurance would
not pay for that procedure. In the same way, if a parent
would like their child to be above-average in height, the
funding for this genetic modification for enhancement would
have to come out of their pocket and their insurance
provider would not help cover the cost. On the other hand,
if someone has a broken arm, their insurance provider would
help cover the cost of the treatment for that patient. In
the same way, if a parent had their future child’s genome
sequences and was informed that they may have a genetic
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disease, the insurance would help cover the cost for the
genetic modification for therapy in that instance.

How does this effect the impoverished of Appalachia?
If insurance companies in the United States follow by
this precedent and genetic therapy is covered by insurance
companies country-wide, Appalachians with health insurance
will be able to benefit from the health-related aspects of
the CRISPR-Cas9 system. However, the other modifications
that are for the purpose of enhancement will be costly and
will come out-of-pocket from expecting parents who would
like to genetically enhance their child. Therefore, only
wealthy individuals will have the ability to genetically
enhance and design their children. Because of this, it is
very likely that the poor of Appalachia will fall behind in
things such as scholastics and athletics, because wealthier
areas of the country would be able to afford genetic
enhancement for the benefit of greater intelligence and
physicality.
Additionally, the religious backbone of Appalachia may
affect how parents feel about genetic modification. As more
and more technology is discovered, there are more and more
ways that parents can then neglect their children by
withholding certain technologies from them(Hammond, 2010).
13

Hammond argues that in a range of cases, parents will have
a moral obligation to use genetic treatments to prevent
serious disabilities. However, this presents an issue if
the parents cannot pay for this treatment.

Ethical Stances Regarding Genetic Modification
Thomas H. Murray
Thomas H. Murray’s “Stirring the ‘Designer Baby’ Pot”
also ventures into the ethical dilemmas surrounding genetic
manipulation for health and wellness versus genetic
manipulation for enhancing traits that will not affect
health whatsoever. He concludes that the ethical
discussions about genetic manipulation cannot be postponed
forever. He adds that in the future, “it would be a great
public serve to provide a sober assessment of the choices
that would-be parents increasingly face, and to encourage
respectful dialogue about the meaning of parenthood and the
worth of a child so that the parent and children can
flourish together (Murray, 2014). This would help to
prevent parents from making decisions like having genetic
testing done for any other reason than for the best
interest of the child. Still, no policy has been made
regarding the allowance or distribution of modification or
enhancement. However, trivial things like sex-selection are
14

still controversial and are debated on whether they are
ethical or not. Regardless, “legislation, regulation, and
professional guidelines depend on widely shared public
values and their legitimacy” (Murray).

The public will

have to decide what their priorities are regarding the
genetic modification of future generations.

David Resnik and Daniel Vorhaus
Some views on genetic modification are strictly for or
against the technology. David Resnik and Daniel Vorhaus
break down the authenticity argument, uniqueness argument,
freedom argument, and the giftedness argument and explain
how each are unsound. They do so by explaining that each of
these popular arguments assume a strong genetic
determinism. Determinism is “usually equated with the
problem of free will: we are compelled to make the choices
that we make as a result of previous circumstances, and
cannot make choices that are genuinely free.” Genetic
determinism is defined as the view that genes cause traits.
They argue this definition is not precise enough and
therefore causes the other arguments against genetic
modification to be false.

15

Michael J. Sandel
In Michael J. Sandel’s “The Case Against Perfection:
What’s Wrong with Designer Children, Bionic Athletes, and
Genetic Engineering,” he argues that new breakthroughs in
genetics present humanity with both a “problem and a
predicament” (Sandel). The promise, he explains, is that
someday there will be a way to prevent or cure a multitude
of genetic diseases, and the predicament is the knowledge
that genetic modification for purposes of advancing persons
is possible with these newfound genetic technologies.
Sandel concludes that the reason genetic modification makes
individuals uneasy is because genetic manipulation
threatens to eliminate mankind’s appreciation of life as
what he says can only be described as a gift, and to leave
“us with nothing to affirm… outside our own will” (Sandel).
First, according to Sandel, there are four major areas
that genetic manipulation would be used: muscles, memory,
height, and sex selection. Other ethicists have approached
genetic modification in a similar way. With each, he
explains why it would be modified, what some claim is the
reason for people’s unease, and a rebuttal as to why that
is not the case. For example, Sandel describes reasons that
gene therapy would be readily encouraged and accepted for
16

degenerative muscle diseases. However, when it comes to
improving the musculature of unborn children, this could
bring some concern to many individuals. “Why?” he asks.
Many people explain their discomfort with the idea of
improving or enhancing the muscle mass of embryos because
they would grow into genetically enhanced athletes that
would have a genetic advantage over other (non-genetically
modified) individuals. They feel as if it would be unfair
to persons who were not genetically enhanced prior to being
born. Sandel rebuttals this claim by asserting that there
is a fundamental flaw in that argument. He argues many
successful athletes have natural genetic advantage over
others by luck of the genetic draw. Some are naturally
taller, have greater muscle mass, and were born with traits
that allow them to be exemplary athletes. Consequently, he
Sandel concludes people’s unease with genetic enhancement
cannot stem from feelings of unfairness to those who are
not genetically altered.
He continues discussing each of the other three major
areas for manipulation, describing how each causes unease
but cannot be explained away by what most individuals would
claim causes them to be uncomfortable with the idea of the
manipulation. In regard to memory, he says that people are
concerned that it would generate an unequal distribution of
17

enhancement, creating what could be considered two races of
people. He claims that this argument is invalid because it
ignores the moral question at hand: would the enhancement
of certain persons’ memory dehumanize them, or would the
poorer community of people that were not enhanced be put at
an unfair disadvantage? The arguments are then similar in
both height and sex selection: the claims of unease do not
come from where most people assume. It must come from
somewhere deeper than what it seems to on the surface.
His conclusion is that this unease is sourced from the
threat to our appreciation of life as something persons
were given, not something that was controlled, and then
‘because of this newfound control, persons would be left
with nothing to affirm or behold that was any further than
their own freewill.

The Principles of Biomedical Ethics
The importance of biomedical ethics must be explored
in order to begin to delve into the moral implications of
genetic modification. Biomedical ethics must be involved in
any scientific decision in order to regulate proceedings
and protect individuals involved. Marcia Miki Sato’s “The
influences of different socioeconomic scenarios in
bioinformatics and biotechnology: The ethical issues
18

arising from technological advances,” marries
bioinformatics and biotechnology to convey the importance
of biomedical ethics within the two fields. She begins by
explaining how that ethics in science becomes a complex
issue, arguing that “Ethics should not be segregated into
different fields as it assumes ideas of boundaries and
stable values. However, science and society values are in
constant transformations, which hinders the imposition of
ethical values to science” (Sato, 2016).
She analyzes the public, private, and academic spheres
in various situations regarding agriculture, genetic
modification, genetic information, and biological research
and addresses similar case studies of genetic information
and explores how they were handled. Consistently, she
supports the idea that “Ethics should not create obstacles
to the scientific development, but to ensure that moral
values are not deteriorated” (Sato). Biomedical ethics are
to enhance the proceedings of scientific developments,
helping each of them to be as successful as they can be
while putting the least amount of risk on individuals or
their surroundings. In the end, she concludes that “there
is no binary way to answer bioethical issues” (Sato), but
without an analysis of the consequences of the advances in
biotechnology, the “essence of being human” (Sato) is at
19

risk. Although it would be easiest if biomedical ethical
principles gave us straight forward answers, the decisions
made regarding regulation and policy will most always be
complex. However, the ethical decisions must be made in
order to preserve our humanity. For this reason, a clear,
concise, biomedical ethical policy regarding genetic
modification is imperative.
It is appropriate to explore the principles of
biomedical ethics to use as a guide for the construction of
government regulations for the equal and fair distribution
of genetic modification and manipulation with CRISPR-Cas9.
The four principles, each of which being conditional, are
as follows:
1.

The principle of respect for autonomy; this

enforces the notion that medical professionals should
not hinder the proficient implementation of the
autonomy of the patient. Autonomy refers to a person’s
ability to make their own choices in their lives,
acting with stringency and self-will in their
judgements. Another term for autonomy is “self-rule.”
The ability of a person to be able to give their own
medical consent has many qualifications—all of which
could be strongly associated with the patient’s
competency. If one cannot give consent, the patient’s
20

living will is consulted, or if there is no living
will (especially in the case of genetically modified
embryos) the surrogate decision maker is consulted (in
the case of embryos, the parents).
2.

The principle of non-maleficence; this enforces

the notion that medical professionals should not act
in ways that would cause harm or discomfort to
patients. The distinction between non-maleficence and
the following principle is that non-maleficence can be
met by doing nothing. An example of non-maleficence
would be to not kill or cause unnecessary and
unbeneficial pain.
3.

The principle of beneficence; this enforces the

notion that medical professionals should act in ways
that will benefit the wellbeing and health of the
patient. This principle is different from nonmaleficence in that it requires action on the part of
the participant.
4.

The principle of justice; this enforces the

notion that health care and how that health care is
payed for should be distributed in accordance with the
demands of justice. (Degrazia, et.al, 2011)
These four principles should be used to shape the
allocations for the just distribution of genetic
21

modification and manipulation along with the three ethical
principles of prioritarianism, utilitarianism, and equality
to create the fairest policy for all people. In using these
principles in accordance with each other, any question of
importance in each of them could be resolved quickly and
effectively. Previously, it was stated that each of the
principles are conditional and this stands true. One
principle may out-weigh another in one situation and be
equally important in another. This flexibility and
adaptability allows for the specificity of each case as it
presents itself.

Other Ethical Principles
The four principles of biomedical ethics can be used
to shape the allocations for the just distribution of
genetic modification and manipulation if paired with the
three ethical principles of prioritarianism,
utilitarianism, and equality. This would allow for the
creation of the fairest policy for all individuals. In
using these principles in accordance with each other, any
question of importance in each of them could be resolved
quickly and effectively. Previously, it was stated that
each of the principles are conditional and this stands
true. One principle may out-weigh another in one situation
22

and be equally important in another. This flexibility and
adaptability allows for the specificity of each case as it
presents itself.

Prioritarianism
The first, prioritarianism, is one of the moral
principles that individuals argue is what must be followed
to make fair and easy government regulations and
allocations for the just distribution of treatments
surrounding genetic manipulation and modification.
Prioritarianism is a principle adjoining the ideas of
favoring or having a preference for the individuals who are
considered to be the worst-off. Examples of this would be
to prioritize the sickest first which “aids those who are
suffering right now; appeals to the ‘rule of rescue’”
(Persad 260). Therefore, if someone from Appalachia was
worse-off than someone in a wealthier area, the offspring
in Appalachia would be taken care of first because of the
beneficence and justice principles. This would help to
distribute care ethically regardless of the economic status
of the parents.
However, some argue that the sickest people are the
worst-off and therefore may benefit the least from
treatment. For example, if someone had stage 4 cancer,
23

treating them may not be considered as ethical as treating
a baby who has a better chance of surviving for a longer
period of time. However, this is not the case with genetic
modification. The sickest people in genetic modification
are the offspring with the most genetic diseases or
disabilities. If genetic modification is perfected, the
sickest will benefit the most in this circumstance. The
sickest would be individuals with fatal genetic diseases
that would exterminate them either before they were born or
soon afterwards.
Additionally, by using the principles of biomedical
ethics as a guide, the principle of beneficence enforces
the notion that the medical professionals should help the
sickest first in genetic situations because it will benefit
the wellbeing and health of the patient.

Utilitarianism
To continue, utilitarianism is another of the moral
principles that individuals argue is what must be followed
in order to construct fair and simple government
regulations and allocations for the just distribution of
treatments surrounding genetic manipulation and
modification. Utilitarianism is a principle surrounding the
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ideas of maximizing the total benefits for all people.
Examples of this would be to focus incentives on saving as
many lives as possible which “[benefits] the greatest
number; avoids the need for comparative judgements about
quality or other aspects of lives” (Persad 260) and to
focus incentives on “prognosis or life-years
saved…[which]... maximizes life-years produced” (Persad
260).
Conversely, others argue that implementing an
incentive that promotes saving as many lives as possible is
“insufficient on its own” (Persad 269). If this principle
is part of a larger group of incentives, including
promoting the treatment of the sickest first, more people
would be saved in a more ethical and just manner: infants
who would have died before birth could live, while infants
who would have lived to old age but gotten osteoporosis may
not be put first on the list for service. In the same way,
offspring that would be born with a genetic disease would
be treated before another offspring that would be born with
below-average height.
Even others maintain that executing a motivation that
promotes increasing life-years ignores the issue of
distribution and quantity. As stated beforehand however, if
this principle is part of a larger group of incentives,
25

including promoting the treatment of the sickest and worstoff first, and promoting the saving of the most lives, more
people would be treated appropriately according to the
principles biomedical ethics.

Justice, non-maleficence,

and beneficence are all maintained in these circumstances.

Equality
Finally, equality is one of the moral principles that
individuals argue is what must be followed to create
reasonable and simple government regulations
and allocations for the evenhanded distribution of
treatments surrounding genetic manipulation and
modification. Equality is a principle surrounding the idea
of treating all individuals alike, and placing everyone on
level ground. An example of this would be to implement a
lottery system where little information is needed about
patients and any corruption is minimized in the system.
Some argue that the lottery is blind to relevant
factors. For example, “random decisions between someone who
can gain 40 years and someone who can gain only 4 months”
(Persad 267) are not appropriate decisions to make by
lottery. Response: Again, if this principle is part of a
larger group of incentives, including promoting the
treatment of the sickest first, promoting the saving of the
26

most lives, and promoting the increasing of live-years,
more people would be saved in a more efficient and fair
manner.
Still, these are all situations in which all three
principles, prioritarianism, utilitarianism, and equality
all work together and promote each other. But what about in
situations where they do not? What happens when two of the
three conflict? One must look to the principles of
biomedical ethics. Each of the four principles of
biomedical ethics, respect for autonomy, beneficence, nonmaleficence, and justice can all act together as guides for
what to do in each specific circumstance.
For example, what would happen if all the parents of
the offspring needing genetic modification were put into a
lottery? The individuals chosen would not necessarily be
the sickest or the worst-off. The individual may also not
be in as severe a case as another embryo. Therefore, the
principles of biomedical ethics would have to be in place
in the lottery. It would somehow have to be separated by
the sickest or worst-off, so the beneficence and nonmaleficence principles are included. In another example,
there may be two equally bad cases of genetic disease. The
order of treatment would have to be determined in another
way other than promoting the life years or lives saved.
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This is when a lottery could be used, to maintain the
justice principle of biomedical ethics. This allows the
distribution of care to be just, as it was randomly
assigned by lottery so both cases had an equal chance of
being treated first.
All of this leads back to the beginning point, that
without these principles, the poor of Appalachia would be
left behind. Instead of the wealthiest of people enhancing
their children to be taller, smarter, and more talented,
only the sickest or worst-off of embryo would be treated in
order of severity, not willingness or ability to pay.

Conclusions
Recent advances in biomedical technology have
increased exponentially and therefore, great deal of
ethical disputes that have introduced themselves into the
scientific and medical communities. The just distribution
of health care is still a highly-contested topic in the
ethical and medical fields. In America, this problem
infests the impoverished of the country.
The lack of wealth in Appalachia results in an absence
of proper health care for the citizens existing there.
Government regulations such as implementing systems focused
around utilitarianism, prioritarianism, and equality could
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help to reverse this effect of poverty with the just
distribution of genetic modification and manipulation, but
the principles of biomedical ethics must contribute to the
making of any policies or allocation system. Without the
principles of respect for autonomy, beneficence, nonmaleficence, and justice, the three ethical principles
previously stated cannot stand.
In conclusion, government regulation or policy must be
instated for the protection of all persons, including the
underserved and impoverished of Appalachia. The lack of
wealth in Appalachia results in an absence of proper
healthcare for the citizens existing there. Government
regulations such as implementing the principles of
biomedical ethics must come to fruition sooner than later.
Finally, without government regulation of the
distribution of genetic modification and medical
enhancements, the underprivileged of Appalachia will suffer
immeasurably from the absence of protection against genetic
ailments and disorders and absence of opportunity for
genetic improvements and will eventually fall further
behind more developed and wealthy areas concerning their
health and quality of life.
Fortunately, great advances in science will continue
to occur far into the future. Unfortunately, these advances
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will be accompanied by new ethical problems that must be
solved for the wellbeing of all persons. A great deal of
ethical disputes that have introduced themselves into the
scientific and medical communities will be followed by new
ethical dilemmas. However, if policy can be instated now,
it can act as a precedent for future policy, making the
process to protect underserved persons and their
surroundings much more efficient.

30

Works Cited
Altieri, M. A., & Rosset, P. (2000). Ten reasons why
biotechnology will not help the developing world.
Erwin, Paul Campbell, MD, MPH, “Poverty in America: How
Public Practice Can Make a Difference, American
Journal of Public Health, 98, 9, 2008.
Hammond, Jessica. "Genetic Engineering to Avoid Genetic
Neglect: From Chance to Responsibility." Bioethics,
vol. 24, no. 4, May 2010, pp. 160-169.
Harris, John. "Germline Manipulation and Our Future
Worlds." American Journal of Bioethics, vol. 15, no.
12, Dec. 2015, pp. 30-34.
Hsu, Patrick D et al. “Development and applications of
CRISPR-Cas9 for genome engineering” Cell vol. 157,6 (
2014): 1262-78.
Juengst, Eric T. "Crowdsourcing the Moral Limits of Human
Gene Editing?." Hastings Center Report, vol. 47, no.
3, May 2017, pp. 15-23.
Mao, X. (1998). Chinese geneticists' views of ethical
issues in genetic testing and
screening: evidence for eugenics in China. The
American Journal of Human Genetics, 63(3), 688-695.
of Bioethics, vol. 15, no.12, Dec. 2015,pp. 52-53.

31

Murray, Thomas H., “The Worth of a Child” (1996) Univ. of
California Press, Berkeley.
Murray, Thomas H., “Stirring the Simmering ‘Designer Baby’
Pot,” Science, 343, 6176, 208 1210, 2014.
Neuhaus, Carolyn P. and Arthur L. Caplan. "Genome Editing:
Bioethics Shows the Way." Plos Biology, vol. 15, no.
3, 16 Mar. 2017, pp. 1-5.
Nicol, Dianne et al. “Key challenges in bringing CRISPR
mediated somatic cell therapy into the clinic” Genome
medicine vol. 9,1 85. 25 Sep. 2017.
Persad, Govind; Wertheimer, Alan; Emanuel, Ezekiel J.,
“Principles for Allocation of Scarce Medical
Interventions,” The Lancet.
Ran, F Ann et al. “Genome engineering using the CRISPR-Cas9
system” Nature protocols vol. 8,11 (2013): 2281-2308.
Reis, A., Hornblower, B., Robb, B., et. al. “CRISPR/Cas9 &
Targeted Genome Editing: New Era in Molecular Biology”
NEB Expression, Issue 1, (2014).
Resnik, David B. and Daniel B. Vorhaus. "Genetic
Modification and Genetic Determinism." Philosophy,
Ethics & Humanities in Medicine, vol. 1, Jan. 2006,
pp. 9-11.
Sander, Jeffry D and J Keith Joung. “CRISPR-Cas systems for

32

editing, regulating and targeting genomes” Nature
biotechnology vol. 32,4 (2014): 347-55.
Sankar, Pamela L. and Mildred K. Cho. "Engineering Values
into Genetic Engineering: A Proposed Analytic
Framework for Scientific Social Responsibility."
American Journal of Bioethics, vol. 15, no. 12, Dec.
2015, pp. 18-24.
Sato, Marcia Miki. “The influences of different
socioeconomic scenarios in bioinformatics and
biotechnology: The ethical issues arising from
technological advances” (2016). Thesis. Rochester
Institute of Technology.
Scherz, Paul. "The Mechanism and Applications of CRISPR
Cas9." National Catholic Bioethics Quarterly, vol. 17,
no. 1, Spring2017, pp. 29-36.

33

